Company Research Report: Kurma Partners
Company Overview
Name:
Kurma Partners
Mission:
Kurma Partners aims to transform disruptive scientific discoveries into cutting-edge medicines or medical devices to diagnose and treat severe diseases with high unmet medical need.
Foundation:
Kurma Partners was co-created in 2009 by Thierry Laugel.
Key People:
- Thierry Laugel, Managing Partner
- Rémi Droller, Managing Partner
- Sylvain Cascarino, CFO - Partner
- Peter Neubeck, Partner Germany
- Benjamin Belot, Partner
- Amanda Gett, Partner
- Alain Horvais, Partner
- Daniel Parera, Partner Germany
- Philippe Peltier, Partner
- Jean-François Rivassou, Partner
Headquarters:
24, rue Royale, 75008 Paris, France.
Number of Employees:
No information is available.
Revenue:
No information is available.
Core Competencies:
Kurma Partners is known for its innovative approach in the funding of healthcare and biotechnology in Europe. It focuses on creating and investing in early-stage companies with the potential to emerge as leaders in their respective sectors, particularly in medicines and medical devices for high unmet medical needs.
Products
Product Offering:
Kurma Partners primarily offers investment funds in the healthcare and biotechnology sectors.
Fund Details:
1. Kurma Biofund I
- Description: Investment fund dedicated to life sciences.
- Size: €51 million.
- Closing: 2009.
- Intervention: Seed.
- Sector: Biotechnology, therapeutic.
- Geography: Europe.
2. Kurma Biofund II
- Description: Focus on therapeutic solutions and rare diseases.
- Size: €55 million.
- Closing: 2013.
- Intervention: Company creation, venture.
- Sector: Biotechnology, therapeutic.
- Geography: Europe.
3. Kurma Biofund III
- Description: New therapeutic solutions for high medical needs.
- Size: €160 million.
- Closing: 2018.
- Intervention: Company creation, venture.
- Sector: Biotechnology, therapeutic.
- Geography: Europe, slight US involvement.
4. Kurma Biofund IV
- Description: New fund focusing on high medical need solutions.
- Size: €140 million (First closing).
- Closing: 2024.
- Intervention: Company creation, venture.
- Sector: Biotechnology Therapeutic.
- Geography: Europe and beyond.
5. Kurma Diagnostics
- Description: Investment in diagnostic solutions.
- Size: €35 million.
- Closing: 2015.
- Intervention: Seed.
- Sector: Diagnostic & Diagnostic Digital.
- Geography: France.
6. Kurma Diagnostics II
- Description: Focus on digital diagnostics.
- Size: €83 million.
- Closing: 2021.
- Intervention: Seed.
- Sector: Diagnostic & Diagnostic Digital.
- Geography: Europe.
7. Kurma Growth Opportunities
- Description: Growth capital in therapeutic/non-therapeutic solutions.
- Size: Ongoing €160 million.
- Closing: 2022.
- Intervention: Late-stage Growth and Cross-over.
- Sector: Biotechnology, therapeutic and Diagnostics, HealthTech, MedTech.
- Geography: Europe and beyond.
Key Features:
- Focused on creating companies in Europe and investing in companies across Europe and the US.
- Integrates disruptive scientific research into practical healthcare solutions.
Recent Developments
Recent Developments in the Company:
1. Kurma Biofund IV raised €140 million in its first closing out of a targeted €250 million fund in 2024.
2. Acquisition of Amolyt Pharma by AstraZeneca, a major exit of Kurma Biofund III.
New Products Launched:
No specific product launches mentioned; focus is on investments and fund establishments.
New Features Added to Existing Products:
No significant new features disclosed.
Partnerships and Collaborations:
- PanTera Financing: Kurma Growth Opportunities and others invested €93 million to advance actinium-225 production.
- Vico Therapeutics Funding: Series B funding totaling €65.8 million in collaboration with Seroba.
Conclusion
Kurma Partners stands as a key player in European healthcare and biotechnology investment, marked by its strategic fund establishment and disposition towards transforming scientific research into viable healthcare solutions. The company's recent developments and fund initiatives strongly underscore its commitment to high-impact healthcare innovations.
